Author(s): Diksha, Prevesh Kumar, Navneet Verma


DOI: 10.52711/0974-360X.2021.00508   

Address: Diksha*, Prevesh Kumar, Navneet Verma
Assistant Professor, Faculty of Pharmacy, IFTM University, Moradabad (U.P.).
*Corresponding Author

Published In:   Volume - 14,      Issue - 5,     Year - 2021

In recent years the treatment of infectious diseases and immunisation has undergone a revolutionary shift. Not only a large number of disease-specific biological have been developed, but also contortion has been made to deliver these biological effectively. Conventional dosage forms are unable to deliver the drug in accordance with a predetermined rate and release therapeutically effective amount of drug at the site of action. The vesicular systems of niosomes, having bilayer structure assembled by nonionic surfactants are able to enhance the bioavailability of a drug to a predetermined area for a particular time period. In recent years various comprehensive researchs carried over niosome as a drug carrier and proved to be a promising drug carrier, which has potential to reduce the side effects of drugs and increased therapeutic effectiveness in various diseases. This narrative review describes fundamental aspects of niosomes, formulation methods, methods of characterization, recent advances in niosomal drug delivery.

Cite this article:
Diksha, Prevesh Kumar, Navneet Verma. An Overview on Niosomes: As an Auspesious Drug Delivery System on the Bases of Application. Research Journal of Pharmacy and Technology. 2021; 14(5):2896-2. doi: 10.52711/0974-360X.2021.00508

Diksha, Prevesh Kumar, Navneet Verma. An Overview on Niosomes: As an Auspesious Drug Delivery System on the Bases of Application. Research Journal of Pharmacy and Technology. 2021; 14(5):2896-2. doi: 10.52711/0974-360X.2021.00508   Available on:

1.    Diljyot, K. Niosomes: a new approach to targeted drug delivery. Int J Pharm Phytopharmacological. Res. 2012; 2(1): 53-54.
2.    Shinde NG, Nagesh H, Aloorkar, Ajit S, Kulkarni. Recent advances in vesicular drug delivery system. Res. J Pharm Dosage Forms Technology. 2014; 6(2): 110-120.
3.    Biju SS, Talegaonkar S, Mishra PR and Khar RK. Vesicular systems: an overview. Ind J Pharm Sci. 2006; 141-153.
4.    Jadhav MS, Morry P, Karpe M, Kadam V. Novel vesicular system- an overview. J Applied Pharm Sci. 2012; 2(1): 193-202.
5.    Chandu, P, Arunachalam, A, Jeganath, S, Yamini K, Tharangini K, Chaitanya G. Niosomes: a novel drug delivery system. Int J Novel Trends Pharm Sci. 2012; 2(4): 25-29.
6.    Kazi KM., Mandal AS. and Kuotsu K. Niosome: a future of targeted drug delivery systems. J Adv Pharm Technol Res. 2010; 1(4): 374-380.
7.    Kar K, and Sudheer P. Formulation and evaluation of niosomal drug delivery system of Ketoprofen. RGUHS J Pharm Sci. 2015; 5(4): 173-180.
8.    Mishra N, Srivastava V, Kaushik A, Chauhan V, Srivastava G. Formulation and in-vitro evaluation of niosomes of Aceclofenac. J Scient Innovat Res. 2014; 3(3): 337-34.
9.    Thakur V, Arora S, Prashar B, Patil V. Niosome and liposome- vesicular approach towards transdermal drug delivery. Int J Pharm Chem Sci. 2012; 1(3): 981-987.
10.    Udupa N, Jain NK. Niosomes as drug carriers., editor. Controlled and novel drug delivery. 1st edition. New Delhi CBS Publishers 2002.
11.    Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. Preparation and properties of niosomes- non-ionic surfactant vesicles. J Pharm Pharmacol. 1985; 37: 863–870.
12.     Jiao J. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv Drug Del Rev. 2008; 60(15): 663–1673.
13.    Gharbavi M, Amani J, Kheiri H, Danafar H, and Sharafi, A. Niosome: a promising nanocarrier for natural drug delivery through blood- brain- barrier. Adv Pharmacol Sci. 2018; 1-15.
14.    Didem Ag, Seleci M, Walter JG, Stahl F, and Scheper T. Niosomes as nanoparticular drug carriers: fundamentals and recent applications. J Nanomaterials. 2016; 1-13.
15.    Uchegbu IF and Florence AT, Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv Colloid Interface Sci. 1995; 58(1): 1–55.
16.    Shahiwala A and Misra A, Studies in topical application of niosomally entrapped nimesulide, J Pharm Pharmaceu Sci. 2002; 5(3): 220–225.
17.    Sharma V, Anandhakumar S, and Sasidharan M. Selfdegrading niosomes for encapsulation of hydrophilic and hydrophobic drugs: an efficient carrier for cancer multi-drug delivery. Materials Sci and Eng . 2015; 56: 393– 400.
18.    Caracciolo G, Pozzi D, Caminiti R. Effect of hydration on the structure of solid-supported niosomal membranes investigated by in situ energy dispersive X-ray diffraction. Chem Physi Letters. 2008; 462(4-6): 307–312.
19.    Nasseri B. Effect of cholesterol and temperature on the elastic properties of niosomal membranes. Int J Pharmace. 2005; 300 (1-2): 95–101.
20.    Marianecci C, Marzio LD, Rinaldi F. Niosomes from 80s to present: the state of the art. Adv Colloid Inter Sci. 2014; 205: 187–206.
21.    Kumar GP and Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery-an overview. Acta Pharmaceutica Sinica B. 2011; 1(4): 208–219.
22.    Biswal S, Murthy PN, J Sahu J, Sahoo P, and Amir F. Vesicles of non-ionic surfactants (niosomes) and drug delivery potential. Int J Pharmaceutic Sci Nanotech. 2008; 1: 1–8.
23.    Israelachvili JN. Intermolecular and surface forces, 1985, Academic Press, New York, NY, USA, 1985.
24.    Uchegbu IF and Vyas SP, Non-ionic surfactant based vesicles (niosomes) in drug delivery, Int J Pharmace. 1998; 172(1-2): 33–70.
25.    Khalil RA and Zarari AH. Theoretical estimation of the critical packing parameter of amphiphilic self-assembled aggregates. Applied Surface Sci.2014; 318: 85–89.
26.    Mandal S, Banerjee C, Ghosh S, Kuchlyan J, and Sarkar N. Modulation of the photophysical properties of curcumin in nonionic surfactant (Tween-20) forming micelles and niosomes: a comparative study of different microenvironments. J Phys Chem B.2013; 117(23): 6957– 6968.
27.    Moghassemi S and Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Controlled Release. 2014; 185(1): 22–36.
28.    Akhilesh D, Bini KB, and Kamath JV. Review on span-60 based non-ionic surfactant vesicles (niosomes) as novel drug delivery. Int J Res Pharmaceu Biomed Sci. 2012; 3: 6–12.
29.    Liu T, Guo R, Hua W, and Qiu J. Structure behaviors of hemoglobin in PEG 6000/Tween 80/Span 80/H2O niosome system Colloids and Surfaces A: Physicochemical and Engineering Aspects.2007; 293(1–3): 255–261.
30.    Agarwal S, Bakshi V, Vitta P, Raghuram AP, Pandey S, and Udupa N. Effect of cholesterol content and surfactant HLB on vesicle properties of niosomes. Ind J Pharmaceu Sci. 2004; 66(1): 121–123.
31.    Mokhtar M, Sammour OA, Hammad MA, and Megrab NA. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharmaceu.2008; 361(1-2): 104–111.
32.    Junyaprasert VB, Teeranachaideekul V, and Supaperm T. Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes. AAPS Pharm Sci Tech 2008; 9(3): 851–859.
33.    Suzuki K. and Sokan K. The Application of Liposomes to Cosmetics. Cosmetic and Toiletries. 1990; 105: 65-78.
34.    Makeshwar Kshitij B, Wasankar Suraj R. Niosome: a novel drug delivery system. Asian J Pharmaceu Res. 2013; 3(1): 16-20.
35.    Bhaskaran S, Panigrahi L. Formulation and evaluation of niosomes using different nonionic surfactant. Ind J Pharm Sci. 2002, 63: 1-6.
36.    Khandare JN, Madhavi G and Tamhankar BM. Niosomes novel drug delivery system. The East Pharmacist. 1994; 37: 61-64.
37.    Madhav NVS and Saini A. Niosomes: A novel drug delivery system. Int J Res Pharm Chem. 2011; 1(3): 498- 511.
38.    Kaur H, Dhiman S, Arora S. Niosomes: a novel drug delivery system. Int J Pharmaceu Sci Rev Res. 2012; 15(1): 22, 113-120.
39.    Naresh RA, Chandrashekhar G, Pillai GK, Udupa N. Antiinflammatory activity of niosome encapsulated Diclofenac sodium with Tween-85 in Arthitic rats. Ind J Pharmacol. 1994, 26: 46- 48.
40.    Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998; 172: 33–70.
41.    Jayaraman SC, Ramachandran C, Weiner N. Topical delivery of erythromycin from various formulations: an in vivo hairless mouse study. J Pharm Sci. 1996; 85: 1082–1084.
42.    Hao Y, Zhao F, Li N, Yang Y, Li K. Studies on a high encapsulation of colchicines by a noisome system. Int J Pharm, 2002; 244: 73-80.
43.    Chauhan S, and Luorence MJ. The preparation of polyoxyethylene containing non-ionic surfactant. vesicles. J Pharm Pharmacol. 1989; 41: 66.
44.    Blazek WAI and Rhodes DG. Sem imaging predicts quality of niosomes from maltodextrin-based proniosomes. Pharm Res. 2001; 18: 656- 661.
45.    Bayindir ZS and Yuksel N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharmaceu Sci. 2010; 99(4): 2049–2060.
46.    Tavano L, Aiello R, Ioele G, Picci N, and Muzzalupo R. Niosomes from glucuronic acid-based surfactant as new carriers for cancer therapy: preparation, characterization and biological properties. Colloids and Surfaces B: Biointerfaces2014; 118: 7–13.
47.    Priprem A, Janpim K, Nualkaew S, and Mahakunakom P. Topical niosome gel of Zingiber cassumunar Roxb extract for anti- inflammatory activity enhanced skin permeation and stability of compound. AAPS Pharm Sci Tech. 2016; 17(3); 631–639.
48.    Huaand W, Liu T. Preparation and properties of highly stable innocuous niosome in Span80/PEG400/H2Osystem. Colloids and surfaces A: Physicochem Eng Aspects. 2007; 302: 377–382.
49.    Manosroi A, Ruksiriwanich W, Abe M, Sakai H, Manosroi W, and Manosroi. J Biological activities of the rice bran extract and physical characteristics of its entrapment in niosomes by supercritical carbon dioxide fluid. J Supercritical Fluids. 2010; 54(2): 137–144.
50.    Manosroi A, Chutoprapat R, Abe M, and Manosroi J. Characteristics of niosomes prepared by supercritical carbon dioxide (scCO2) fluid. Int J Pharmaceu 2008; 352(1-2): 248–255.
51.    Liu T, Guo R, Hua W, and J. Qiu J. Structure behaviors of haemoglobin in PEG6000/Tween80/Span80/H2O niosome system. Colloids and Surfaces A: Physicochem Eng Aspects. 2007; 293(1–3): 255–261.
52.    D. Pando, G. Guti´errez, J. Coca, and C. Pazos, “Preparation and characterization of niosomes containing resveratrol,” Journal of Food Engineering, vol.117, no.2, pp.227–234, 2013.
53.    L. Tavano, R. Muzzalupo, L. Mauro, M. Pellegrino, S. Ando and N. Picci, “Transferrin-conjugated Pluronic niosomes as a new drug delivery system for anticancer therapy,” Langmuir, vol.29, no.41, pp.12638–12646, 2013.
54.    Tabbakhian M, Daneshamouz S, Tavakoli N, and Jaafari MR. Influence of liposomes and niosomes on the in vitro permeation and skin retention of finasteride. Iran J Pharmaceu Sci. 2005; 1(3): 119–130.
55.    Mehta SK, and Jindal N. Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of antitubercular drugs.Colloids and Surfaces B: Biointerfaces,.2013; 101: 434–441.
56.    AWaddad AY, Abbad S, Yu F. Formulation, characterization and pharmacokinetics of Morin hydrate niosomes prepared from various non-ionic surfactants. Int J Pharmace. 2013; 456(2): 446–458.
57.    Hao Y, Zhao F, Li N, Yang Y, and Li K. Studies on a high encapsulation of colchicine by a niosome system. Int J Pharmaceu. 2002; 244(1-2): 73–80.
58.    Akhilesh D,. Bini KB, and Kamath JV. Review on span-60 based non-ionic surfactant vesicles (niosomes) as novel drug delivery. Int J Res Pharmaceu Biomed Sci. 2012; 3: 6–12.
59.    Tarekegn A, Joseph NM , Palani S, Zacharia A, Ayenew Z. Niosomes in targeted drug delivery: some recent advances. Inte J Pharmaceu Sci Res. 2010; 1(9): 1-8.
60.    Abdelbary G and Gendy N EL. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS Pharm Sci Tech. 2008; 9(3): 740–747.
61.    Verma NK, Roshan A. Niosomes and its application. Int J Res Pharm Life Sci. 2014; 2(1): 182-184.
62.    Kong M, Park H, Feng C, Hou L, Cheng X, and Chen X. Construction of hyaluronic acid noisome as functional transdermal nanocarrier for tumor therapy. Carbohydrate Polymers. 2013; 94(1): 634–641.
63.    Narang A and Mahato R. Targeted Delivery of Small and Macromolecular Drugs, CRC Press, 2010.
64.    Ag D, Bongartz R, Dogan LE. Biofunctional quantum dots as fluorescence probe for cell-specific targeting. Colloids and Surfaces B: Biointerfaces. 2014; 114: 96–103.
65.    Seleci M, Seleci DA, Ciftci M. Nanostructured amphiphilic star-hyperbranched block copolymers for drug delivery. Langmuir. 2015; 31(15) 4542–4551.
66.    Cosco D, Paolino D, Muzzalupo R. Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5- fluorouracil. Biomed Microdevices. 2009; 11(5): 1115– 1125.
67.    Shaker DS, Shaker MA, and Hanafy MS. Cellular uptake, cytotoxicity and in-vivo evaluation of Tamoxifen citrate loaded niosomes. Int J Pharmaceu. 2015; 493(1-2): 285–294.
68.     Dwivedi A, Mazumder A, Plessis LD, Preez JLD, Haynes RK, and Plessis JD. In vitro anti-cancer effects of artemisone nano-vesicular formulations on melanoma cells. Nanomed Nanotechn Bio Med. 2015; 11 (8): 2041–2050.
69.    Gude RP, Jadhav MG, Rao SGA, and Jagtap AG. Effects of niosomal cisplatin and combination of the same with theophylline and with activated macrophages in murine B16F10 melanoma model. Cancer Biother Radiopharm. 2002; 17(2): 183–192.
70.    Gadde S. Multi-drug delivery nanocarriers for combination therapy. MedChem Comm. 2015; 6(11): 1916–1929.
71.    Pasut G, Greco F, Mero A. Polymer-drug conjugates for combination anticancer therapy: investigating the mechanism of action. J Med Chem. 2009; 52(20): 6499–6502, 2009.
72.    Shilpa S, Srinivasan BP, Chauhan M. Niosomes as vesicular carriers for delivery of proteins and biologicals. Int J Drug Delivery. 2011; 3:14–24.
73.    Terzano C, Allegra L, Alhaique F, Marianecci C, Carafa M. Non-phospholipid vesicles for pulmonary glucocorticoid delivery. Eur J Pharm Biopharm. 2005; 59:57–62.
74.    Lynch JK, Hirtz DG, DeVeber G, and Nelson KB. Report of the national institute of neurological disorders and stroke workshop on perinatal and childhood strok. Pediatrics.2002; 109(1): 116–123.
75.    Shi Y, Jiang X, Zhang L. Endothelium-targeted overexpression of heat shock protein 27 ameliorates blood–brain barrier disruption after ischemic brain injury. Proceedings National Acad Sci. 2017; 114(7): E1243–E1252.
76.    Knowland D, Arac A, Sekiguchi KJ. Stepwise recruitment of transcellular and paracellular pathways underlies blood-brain barrier breakdown in stroke. Neuron. 2014; 82(3): 603–617.
77.    Upadhyay RK. Drug delivery systems, CNS protection, and the blood brain barrier. BioMed Res Int. 2014; 2014: 1- 37.
78.    Bedolla PC, Walter FR, Veszelka S, and Deli MA. Role of the blood–brain barrier in the nutrition of the central nervous system. Archives Med Res. 2014; 45(8): 610–638.
79.    Lu CT, Zhao YZ, Wong HL, Cai J, Peng L, and Tian XQ. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomed. 2014; 9: 2241.
80.    Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharmaceutica Sinica B. 2016; 6(4): 268–286.
81.    Estanqueiro M, Amaral MH, Conceiçao J, and Lobo JMS. Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloids and Surfaces B: Biointerfaces. 2015; 126: 631–648.
82.    Farokhzad OC and Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009; 3(1): 16–20.
83.    Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Delivery. 2011; 63(3): 131–135.
84.    Svenson S and Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug Delivery. 2012; 64: 102–115.
85.    Robinson M, Lee BY, and Leonenko Z. Drugs and drug delivery systems targeting Amyloid-β in Alzheimers disease. 2017,
86.    Fong CW. Permeability of the blood–brain barrier: molecular mechanism of transport of drugs and physiologically important compounds. J Memb Bio. 2015; 248(4): 651–669.
87.    Mujoriya R, Bodla RB, Dhamande KK, Singh D, Patle L. Niosomal drug delivery system: the magic bullet. J App Pharma Sci. 2011; 1: 20-23.
88.    Medda S, Mukhopadhyay S, Basu M K. Evaluation of the in vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. J Antimicrob Chemother. 1999; 44: 791- 794.
89.    Sarkar S, Mandal S, Sinha J, Mukhopadhyay S, Das N, Basu M K. Quercetin: Critical Evaluation as an antileishmanial agent in vivo in hamsters using different vesicular delivery modes. J Drug Target. 2002; 10: 573-578.
90.    Huang YZ, Han G, Wang H, Liang W Q. Cationic niosomes as gene carriers: preparation and cellular uptake in vitro. Pharmazie. 2005; 60: 473-474.
91.    Huang YZ, Gao JQ, Chen JL, Liang WQ. Cationic liposomes modified with non-ionic surfactants as effective non-viral carrier for gene transfer. Colloids Surf B Biointerfaces. 2006; 49: 158-164.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available